Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer

Anticancer Research

Volumn 28, Issue 6 B, 2008, Pages 3997-4002

  Wu, Changping ^a   Jiang, Jingting ^a   Shi, Liangrong ^a   Xu, Ning ^b  

^a SOOCHOW UNIVERSITY   (China)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Cytokine induced killer cells; Immunotherapy; Non small cell lung cancer

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL THERAPY; CONTROLLED STUDY; CYTOMETRY; DESENSITIZATION; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; IMMUNE FUNCTION TEST; KILLER CELL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 58149165343     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun Mj: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
2. Atlanta G: Cancer Facts and Figures 2004. American Cancer Society 2004.
3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311: 899-909, 1995.
4. Grilli R, Oxman AD and Julian JA: Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 11: 1866-1872, 1993.
5. Sandler AB, Nemunaitis J, Denham C, Von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C and Einhorn LH: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 18: 122-130, 2000.
6. Shepherd FA: Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin Oncol 26: 3-11, 1999.
7. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR and Livingston RB: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16: 2459-2465, 1998.
8. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M and Johnson D: Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623-631, 2000.
9. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, Garcia M, Lianes P, Montalar J, Vadell C, Gonzalez-Larriba JL, Nguyen B, Artal A and Rosell R: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 17: 12-18, 1999.
10. Ramanathan RK and Belani CP: Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Semin Oncol 24: 440-454, 1997.
11. Leemhuis T, Wells S, Scheffold C, Edinger M and Negrin RS: A phase 1 trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11: 181-187, 2005.
12. Li HF, Yang YH, Shi YJ, Wang YQ and Zhu P: Cytokine-induced killer cells showing multidrug resistance and remaining cytotoxic activity to tumor cells after transfected with mdr1 cDNA. Chin Med J (Engl) 117: 1348-1352, 2004.
13. Takahashi H, Nakada T and Puisieux I: Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 259: 1460-1463, 1993.
14. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG and Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174: 139-149, 1991.
15. + T-cells to Fas-mediated apoptosis. Cancer Immunol Immunother 49: 335-345, 2000.
16. Kim HM, Kang JS, Lim J, Park SK, Lee K, Yoon YD, Lee CW, Lee KH, Han G, Yang KH, Kim YJ, Kim Y and Han SB: Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch Pharm Res 30: 1464-1470, 2007.
17. + cells derived from T-cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153: 1687-1696, 1994.
18. Scheffold C, Brandt K, Johnston V, Lefterova P, Degen B, Schontube M, Huhn D, Neubauer A and Schmidt-Wolf IG: Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant 15: 33-39, 1995.
19. + killer cells. Ann Hematol 74: 51-56, 1997.
20. Hohen PJ, Gralla RJ, Kris MG and Cox C: Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 2: 213-222, 1994.
21. Hollen PJ, Gralla RJ, Kris MG and Potanovich LM: Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 29A(Suppl 1): S51-8, 1993.
22. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
23. Herberman RB: Cancer therapy by biological response modifiers. Clin Physiol Biochem 5: 238-248, 1987.
24. Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L, Nash RA, Aglietta M and Cignetti A: Alloreactivity and antitumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 20: 841-848, 2008.
25. Linn YC, Lau LC and Hui KM: Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 116: 78-86, 2002.
26. Schmidt-Wolf IG, Lefterova P, Johnston V, Scheffold C, Csipai M, Mehta BA, Tsuruo T, Huhn D and Negrin RS: Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol 169: 85-90, 1996.
27. + GKs) reversed resistance to fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-gamma stimulation. Cancer Biother Radiopharm 23: 342-354, 2008.